FDA Approves Thalomid For Multipple Myeloma Therapy
Filed in archive Drugs, Vaccines and Therapeutics by ruth on May 30, 2006

Celgene announced however that it has found a new application for Thalomid and that the US FDA has granted its Supplemental New Drug Application for the use of Thalomid in combination with dexamethasone
for the treatment of newly diagnosed multiple myeloma, a common type of blood cancer affecting about 50,000 patients in the US.THALOMID is available through a THALOMID Education and Prescribing Safety System, called S.T.E.P.S.(R). Through the use of our S.T.E.P.S. program, more than 130,000 U.S. patients have had safe access to THALOMID since its market introduction in July 1998. This FDA approval for the indication of THALOMID in the treatment of newly diagnosed multiple myeloma allows physicians and their patients to be treated with another therapy option for this incurable blood cancer.
The safety profile of Thalomid has shown quite a number of side effects, ranging from constipation to thrombosis and edema. For more information, see the Thalomid website or the Celgene Press Release.
Permalink: FDA Approves Thalomid For Multipple Myeloma Therapy
Tags:
myeloma
leprosy
biotech
thalomid
therapy
approves+thalomid
multipple+myeloma
myeloma+therapy
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/23175

Mr Wong
